Myositis Collaborative Groups

2nd Annual Summit 2026



Friday, November 6th, 2026

Rosen College of Hospitality Management

Darden Auditorium

9907 Universal Boulevard, Orlando, FL 32819

11:30 AM – 12:30 PM	Networking Lunch Registration, and Poster Set-Up	
12:30 – 12:35 PM	**INTRODUCTION**	
	Welcome Remarks	**Lisa Rider, Jim Minow, Paula Eichenbrenner**
12:35 – 1:45 PM	**SPECIAL TOPIC DISCUSSION: TREAT-TO-TARGET / TREATMENT**	
	PEDIATRICS	
12:35 – 12:50 PM	Treat- to- target strategy in JDM	**Silvia Rosina**
12:50 – 1:00 PM	CARRA effort for consensus treatment plans (CTPs) in moderately severe new-onset JDM	**Kaveh Ardalan**

	ADULT	
1:00 – 1:15 PM	Does current approach to treatment in adult IIM align with treat-to-target model?	**Lisa Christopher-Stine**
1:15 -1:25 PM	A new era in the treatment of cutaneous dermatomyositis	**Alisa Femia**
1:25 -1:45 PM	Panel Discussion	

1:45 – 2:00 PM	LIGHTNING POSTER ROUND: POSTER WINNERS	
2:00 – 3:00 PM	**GENERAL POSTER SESSION** **Sponsor Representative Remarks** **Coffee, Snacks, and Mingling**	
3:00 – 3:20 PM	PATIENT PERSPECTIVE	
3:00 – 3:10 PM	TMA Patient Survey & Needs Assessment Data	**Paula Eichenbrenner**
3:10 – 3:20 PM	Scientific Rigor and Authentic Patient Partnership in the Scientific Process and Outcome Measure Development	**MIHRA Patient Advisory & PATH Patient Voice Council**
3:20 – 4:15 PM	OUTCOME MEASURES & DEFINITIONS OF DISEASE	
3:20 – 3:30 PM	Definition of Low Disease Activity and Remission, an MCTC–IMACS collaboration	**Shiri Keret**
3:30 – 3:40 PM	Definition of Flare, an MCTC–IMACS collaboration	**Iazsmin Bauer Ventura**
3:40 – 3:50 PM	An outcome measure that allows inclusion of skin-predominant dermatomyositis in DM clinical studies	**Victoria Werth**

3:50 – 4:00 PM	Novel Outcome Measures for JDM	**Silvia Rosina**
4:00 - 4:15 PM	Panel discussion	
4:15 -4:30 PM	**BREAK**	
4:30 – 5:00 PM	BIOMARKERS & SURROGATE MEASURES OF DISEASE ACTIVITY	
4:30 – 4:40 PM	CARRA: Translational Medicine for JM Workgroup	**Lauren Covert**
4:40 – 4:50 PM	MCTC: Virtual Monitoring of PFTs	**Pedram Paragomi**
4:50 – 5:00 PM	IMACS: ILD Quantitative Imaging Assessment	**Sharon Bae**
5:00 – 5:20 PM	ON THE HORIZON: NEW & EMERGING PROJECTS AND COLLABORATIONS	
5:00 – 5:10 PM	MIHRA PATH: FDA CDER's Public Private Partnership to Advance Clinical Trial Readiness and Therapeutic Development in Myositis	**Lesley Ann Saketkoo**
5:10 – 5:15 PM	Development of New Core Set Measures	**Didem Saygin**
5:15 – 5:20 PM	iMyoS Terminology Standardization	**Margherita Giannini**
5:20 – 5:30 PM	MYOSITIS GOVERNANCE	
	Updates & Initiatives from iMyoS	**Didem Saygin**

5:30 – 5:35 PM	CONCLUSION
5:35 – 6:30 PM	**RECEPTION** **Sponsor Representative Remarks**